Liulisha

1、Educational Experience

2007/09-2011/07 B.S., Pharmacy, Nanjing Medical University, China

2011/09-2014/07 M.S., Pharmaceutics, China Pharmaceutical University, China. Advisor: Dr. Jianping Liu

2014/09-2018/07 Ph.D., Pharmaceutics, Fudan University, China. Advisor: Dr. Chen Jiang & Dr. Hao Wang

2、Working Experience

2019/02-2021/02, Postdoctoral Associate, University of Michigan, USA. Advisor: Dr. Anna Schwendeman

2021/04-present, Associate research professor, China Pharmaceutical University, China.

1. He, H.¹; Halseth, T. A.¹; Mei, L.; Shen, C.; Liu, L.^*; Schwendeman, A.^*, Nanodisc delivery of liver X receptor agonist for the treatment of diabetic nephropathy. J Control Release 2022, 348, 1016-1027. (IF: 11.467)

2. Ren, L.¹; Li, J. ¹; Liu, L.¹; Wu, W.; Zhao, D.; Zhang, K.; Xin, X.; Yang, L.^*; Yin, L.^*, Resolving hepatic fibrosis via suppressing oxidative stress and an inflammatory response using a novel hyaluronic acid modified nanocomplex. Biomater Sci-Uk 2021, 9 (24), 8259-8269. (IF: 6.843)

3. He, H.¹; Adili, R.¹; Liu, L.¹; Hong, K.; Holinstat, M.; Schwendeman, A.^*, Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice. Sci Adv 2020, 6 (49). (IF: 14.143)

4. He, H.; Liu, L.; Morin, E. E.; Liu, M.; Schwendeman, A.*, Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures. Acc Chem Res 2019, 52 (9), 2445-2461. (IF: 20.834)

5. Liu, L. ¹; Chen, Q.¹; Ruan, C.; Chen, X.; He, X.; Zhang, Y.; Zhang, Y.; Lu, Y.; Guo, Q.; Zhou, W.; Li, C.; Sun, T.; Jiang, C.^*, Nano-engineered lymphocytes for alleviating suppressive tumor immune microenvironment. Appl Mater Today 2019, 16, 273-279. (IF: 8.352)

6. Chen, Q.; Liu, L.; Lu, Y.; Chen, X.; Zhang, Y.; Zhou, W.; Guo, Q.; Li, C.; Zhang, Y.; Zhang, Y.; Liang, D.; Sun, T.; Jiang, C.*, Tumor Microenvironment-Triggered Aggregated Magnetic Nanoparticles for Reinforced Image-Guided Immunogenic Chemotherapy. Adv Sci (Weinh) 2019, 6 (6), 1802134. (IF: 15.840)

7. Liu, L.; Chen, Q.; Ruan, C.; Chen, X.; Zhang, Y.; He, X.; Zhang, Y.; Lu, Y.; Guo, Q.; Sun, T.; Wang, H.; Jiang, C.*, Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity. Theranostics 2018, 8 (11), 2974-2987. (IF: 8.537)

8. Ruan, C.; Liu, L.; Lu, Y.; Zhang, Y.; He, X.; Chen, X.; Zhang, Y.; Chen, Q.; Guo, Q.; Sun, T.; Jiang, C.*, Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma. Acta Pharm Sin B 2018, 8 (1), 85-96. (IF: 6.014)

Liu, L.; Bi, Y.; Zhou, M.; Chen, X.; He, X.; Zhang, Y.; Sun, T.; Ruan, C.; Chen, Q.; Wang, H.*; Jiang, C.*, Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers. ACS Appl Mater Interfaces 2017, 9 (8), 7424-7435. (IF: 8.079)

1. Rational design of novel nanodisc platform for treatment of metabolic disease by designing new mimic peptides and optimizing lipid composition

2. Therapeutic application of extracellular vesicles in the resolution of inflammation.

1.Research Projects

Natural Science Foundation of Jiangsu Province (Award Number: BK20221043)

Scientific Research Starting Foundation of China Pharmaceutical University

2.Representative Research Achievements

Engineering nanodisc with bio-inspired materials for metabolic disease

We are developing new materials that can interact with metabolic mediators and inflammatory response. We seek to investigate the crosstalk between the bio-inspired nanodisc and the metabolic microenvironment and identify materials design criteria, raising the possibility that the nanodisc platform could be harnessed for therapeutics delivery in metabolic disease (e.g., diabetes, atherosclerosis, or vascular dysfuction).